Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.55 USD | +1.11% | +19.42% | -51.13% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 385M |
---|---|---|---|---|---|
Net income 2024 * | -43M | Net income 2025 * | -56M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-8.75
x | P/E ratio 2025 * |
-7.11
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.95% |
Latest transcript on Anavex Life Sciences Corp.
1 day | +1.11% | ||
1 week | +19.42% | ||
Current month | +24.66% | ||
1 month | +19.74% | ||
3 months | -19.75% | ||
6 months | -27.43% | ||
Current year | -51.13% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 15-09-30 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Tom Skarpelos
FOU | Founder | 57 | 04-01-22 |
Jiong Ma
CHM | Chairman | 60 | 21-05-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - | |
0.04% | 1,487 M€ | +9.17% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 4.55 | +1.11% | 942,737 |
24-05-16 | 4.5 | +0.22% | 880,149 |
24-05-15 | 4.49 | +4.18% | 1,472,778 |
24-05-14 | 4.31 | +8.02% | 1,449,520 |
24-05-13 | 3.99 | +4.72% | 1,105,719 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.13% | 385M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- AVXL Stock